Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer.

Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H, Matsuno Y, Tanaka S, Nishihara H, Taketomi A, Todo S.

Br J Cancer. 2012 Jun 26;107(1):137-42. doi: 10.1038/bjc.2012.235. Epub 2012 May 29.

2.

Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer.

Kawamata F, Kamachi H, Einama T, Homma S, Tahara M, Miyazaki M, Tanaka S, Kamiyama T, Nishihara H, Taketomi A, Todo S.

Int J Oncol. 2012 Dec;41(6):2109-18. doi: 10.3892/ijo.2012.1662. Epub 2012 Oct 15.

PMID:
23064529
3.

Mesothelin expression correlates with prolonged patient survival in gastric cancer.

Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S.

J Surg Oncol. 2012 Feb;105(2):195-9. doi: 10.1002/jso.22024. Epub 2011 Jul 20.

PMID:
21780126
4.

C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma.

Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, Takahashi N, Kamiyama T, Nishihara H, Taketomi A, Todo S.

J Gastroenterol. 2014 Jan;49(1):81-92. doi: 10.1007/s00535-013-0773-6. Epub 2013 Mar 20.

PMID:
23512344
5.

Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma.

Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muraoka S, Kamiyama T, Matsuno Y, Ozaki M, Todo S.

Pancreas. 2011 Nov;40(8):1276-82. doi: 10.1097/MPA.0b013e318221bed8.

PMID:
21775916
6.

Importance of lymph vessels in gastric cancer: a prognostic indicator in general and a predictor for lymph node metastasis in early stage cancer.

Nakamura Y, Yasuoka H, Tsujimoto M, Kurozumi K, Nakahara M, Nakao K, Kakudo K.

J Clin Pathol. 2006 Jan;59(1):77-82.

7.

Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas.

Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, Takano Y.

Hum Pathol. 2008 Jul;39(7):1042-9. doi: 10.1016/j.humpath.2007.11.009. Epub 2008 May 14.

PMID:
18482745
8.

Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer.

Kurozumi K, Nishida T, Nakao K, Nakahara M, Tsujimoto M.

World J Surg. 1998 Aug;22(8):853-7; discussion 857-8.

PMID:
9673558
9.

Dynamic expression of CEACAM7 in precursor lesions of gastric carcinoma and its prognostic value in combination with CEA.

Zhou J, Zhang L, Gu Y, Li K, Nie Y, Fan D, Feng Y.

World J Surg Oncol. 2011 Dec 23;9:172. doi: 10.1186/1477-7819-9-172.

10.

Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.

Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH.

Ann Surg Oncol. 2007 Oct;14(10):2748-58. Epub 2007 Aug 7.

PMID:
17680316
11.
12.

Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer.

Yamada T, Watanabe A, Yamada Y, Shino Y, Tanase M, Yamashita J, Miwa T, Nakano H.

Cancer. 1995 Nov 1;76(9):1529-36.

13.

Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery.

Wen Y, Wang Q, Zhou C, Yan D, Qiu G, Yang C, Tang H, Peng Z.

Ann Surg Oncol. 2011 Dec;18(13):3858-67. doi: 10.1245/s10434-011-1668-5. Epub 2011 Mar 26.

PMID:
21442347
14.

Heat Shock Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival.

Giaginis C, Daskalopoulou SS, Vgenopoulou S, Sfiniadakis I, Kouraklis G, Theocharis SE.

BMC Gastroenterol. 2009 Feb 9;9:14. doi: 10.1186/1471-230X-9-14.

15.

Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.

Kolev Y, Uetake H, Iida S, Ishikawa T, Kawano T, Sugihara K.

Ann Surg Oncol. 2007 Oct;14(10):2738-47. Epub 2007 Aug 9.

PMID:
17687613
16.

[Expression of HER-2 and leptin in gastric cancer and their clinical significance].

Geng YT, Qiu JR, Wang R, Su YT, Shu YQ, Yin YM.

Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):764-9. Chinese.

PMID:
22335909
17.

Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas.

Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, Takano Y.

Virchows Arch. 2008 Feb;452(2):147-55. Epub 2007 Dec 14.

18.

Absence of RKIP expression is an independent prognostic biomarker for gastric cancer patients.

Martinho O, Simões K, Longatto-Filho A, Jacob CE, Zilberstein B, Bresciani C, Gama-Rodrigues J, Cecconello I, Alves V, Reis RM.

Oncol Rep. 2013 Feb;29(2):690-6. doi: 10.3892/or.2012.2179. Epub 2012 Dec 10.

PMID:
23232914
19.

Clinical implication of CXCL12 expression in gastric cancer.

Ishigami S, Natsugoe S, Okumura H, Matsumoto M, Nakajo A, Uenosono Y, Arigami T, Uchikado Y, Setoyama T, Arima H, Hokita S, Aikou T.

Ann Surg Oncol. 2007 Nov;14(11):3154-8. Epub 2007 Jul 26.

PMID:
17653799
20.

Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG).

Songun I, van de Velde CJ, Hermans J, Pals ST, Verspaget HW, Vis AN, Menon AG, Litvinov SV, van Krieken JH.

Br J Cancer. 1996 Dec;74(11):1783-8.

Supplemental Content

Support Center